ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

ProQR Therapeutics N.V.NASDAQ: PRQR

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was €705.41K, compared with €0 a year earlier. Trailing-twelve-month cost of revenue was €1.38M.

Context

  • Cost of revenue amounted to 17.0% of revenue in FY2025, up 17.0 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near €705.41K or moves back toward the trailing-twelve-month quarterly average of €344.51K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€705.41K+4.9% QoQ
Last fiscal yearDec 2025
€2.6M— YoY
LTMMar 2026
€1.38M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

EUR · from the income statement

Latest · FY2025
2.6M EUR
Year-over-year change
—

Cost of Revenue vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 10.3% of revenue for PRQR, versus a peer median of 150.0%.
PRQR Competitors
Cost of Revenue for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M USD-23.8%-4.7%—
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+209.9%1217.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M USD-26.6%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.05M USD——698.0%
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M USD-53.4%—94.2%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$16.42M USD+24.9%-18.7%7.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M USD——8.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
MREOMereo BioPharma Group plcLTM Mar 2026$1.03M USD-5.2%—205.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$111K USD———
ZURAZura Bio LimitedLTM Mar 2026$16K USD+220.0%——
Peer median (excluding PRQR) —-5.2%-4.7%150.0%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.